Psychedelics and Depression Treatment Efficacy
A new analysis published in JAMA Psychiatry indicates that psychedelics may not offer greater efficacy than traditional treatments like SSRIs or SNRIs in treating depression. For decades, these conventional medications have served as the primary pharmacological approach for depression.
Achieving functional blinding in psychedelic-assisted therapy (PAT) trials presents a significant challenge. This is due to the marked subjective effects of psychedelics, which allow participants to accurately guess their treatment condition up to 95% of the time.
Only one study has directly compared PAT efficacy to SSRIs, finding no significant differences in treatment outcomes.
Furthermore, a meta-analysis of 24 studies, which compared PAT trials with open-label SSRI/SNRI studies, revealed virtually no difference in Hamilton Depression Rating Scale scores between participants receiving PAT and those on traditional antidepressants.
Researchers also observed a notable "know-cebo" effect within the placebo arms of PAT trials. Participants in these groups experienced significantly worse depression symptoms, a phenomenon attributed to disappointment upon realizing they received a placebo instead of a psychedelic.
This analysis suggests that patient expectations play a substantial role in clinical outcomes and offers a "sobering viewpoint" on PAT's potential.
Legislative Updates on Psychedelics
Kentucky Explores Ibogaine Research Fund
Kentucky legislators are currently considering Senate Bill 77, which proposes the creation of a public-private fund specifically for ibogaine research. The bill has successfully passed the Senate with a vote of 35-2 and is now awaiting consideration in the House. An initial proposal to appropriate $42 million from the state's opioid abatement trust was ultimately removed from the bill.
New Mexico Expands Psilocybin Program Funding
New Mexico Governor Michelle Lujan Grisham recently signed a bill that extends $1 million for the state's medical psilocybin program. The legislation also allocates an additional $300,000 for psilocybin research focused on end-of-life and palliative care. Moreover, a new Medical Psilocybin Treatment Equity Fund will receive $630,000. This significant investment aims to ensure equitable access to treatment, regardless of a patient's ability to pay.
Drug Designation and Professional Accreditation
Bretisilocin Receives EU 'PRIME' Designation
Bretisilocin, a novel psychedelic compound, has become the first psychedelic to receive Priority Medicines (PRIME) designation from the EU’s European Medicines Agency (EMA). This designation is designed to expedite the drug application process. Bretisilocin, initially developed by Gilgamesh Pharmaceuticals and subsequently acquired by AbbVie, is chemically similar to DMT but engineered for a longer duration of effect.
Psychedelic Medicine Association Launches Accreditation Initiative
The Psychedelic Medicine Association (PMA) has established a non-profit arm tasked with creating an accreditation program for psychedelic facilitators. This important initiative seeks to standardize training and oversight across the diverse landscape of psychedelic therapy programs, which currently lack uniform requirements.
Legal Challenges and Other Developments
Oregon Psilocybin Services Faces ADA Lawsuit
An Oregon judge has ruled that Cusker v. Oregon Health Authority, a lawsuit filed by four trained psilocybin facilitators, may proceed. The lawsuit alleges that the Oregon Psilocybin Services’ requirement for all psilocybin sessions to occur in a service center violates the Americans with Disabilities Act (ADA). It claims this restriction limits access for homebound clients with disabilities or terminal illnesses. Attempts by the State of Oregon's attorneys to dismiss the case were denied.
Judge Rules Against Questioning Elon Musk on Ketamine Use
In a separate legal matter, a judge ruled against allowing the questioning of Elon Musk regarding his alleged ketamine use during negotiations with OpenAI. This ruling requires OpenAI to provide more concrete evidence about the mind-altering effects of ketamine specifically relevant to the case.
Ayahuasca Retreat Offers Expanded Healing Perspective
A recent commentary piece in Essence highlighted a writer's experience at an ayahuasca retreat in Costa Rica. The article noted the presence of other Black women and an expanded perspective on healing gained during the retreat.